Τίτλος:
Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: A retrospective analysis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective: Second-line treatment options in advanced urothelial cancer are limited. We investigated the efficacy of a methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) combination after failure of gemcitabine/platinum chemotherapy. Patients and methods: Twenty-five patients with advanced urothelial cancer, who received second-line MVAC after first-line gemcitabine/cisplatin (n = 9) or gemcitabine/carboplatin (n = 16), were included in this retrospective analysis. Results: Twenty-two patients (88%) relapsed within 6 months after first-line treatment. Following MVAC, there were 5 (20%) objective responses. Median follow-up was 20.2 months. Median progression-free survival (PFS) was 3.8 months (95% CI: 2.3-5.2), and median overall survival (OS) was 9 months (95% CI: 6.6-11.4). Eastern Cooperative Oncology Group performance status 0.1 versus 2 was associated with longer PFS (5 months versus 3.3 months, P = 0.049). Response or stabilization of disease during second-line chemotherapy predicted for a significantly longer PFS and OS (7.4 versus 3.5, P = 0.005; 15.5 versus 7, P = 0.046). Conclusions: Second-line MVAC chemotherapy may result in prolonged survival in some patients with refractory disease. Further research in this field is necessary. © 2010 Karadimou et al, publisher and licensee Dove Medical Press Ltd.
Συγγραφείς:
Karadimou, A.
Lianos, E.
Pectasides, D.
Dimopoulos, M.A.
Bamias, A.
Περιοδικό:
Open access journal of urology
Λέξεις-κλειδιά:
carboplatin; cisplatin; doxorubicin; gemcitabine; methotrexate; platinum; vinblastine, adult; advanced cancer; aged; alopecia; anemia; article; cancer combination chemotherapy; cancer relapse; cancer staging; clinical article; controlled study; drug efficacy; drug megadose; drug response; drug treatment failure; female; follow up; histology; human; human tissue; kidney disease; male; multiple cycle treatment; nausea and vomiting; neurotoxicity; neutropenia; overall survival; prediction; progression free survival; recurrent cancer; retrospective study; stomatitis; thrombocytopenia; urogenital tract cancer; visceral metastasis
